Weekly Digests
‹ Back to June

CD4+ T cells take center stage in bladder cancer

June 11, 2020

Bladder cancer is often resistant to anti-PD-1 immunotherapy, however, responses do occur in a small fraction of patients. In order to better understand the specific T cells that mediate tumor rejection in those infrequent cases, Oh and Kwek et al. used single-cell RNAseq and TCRseq to profile T cells from muscle-invasive bladder tumors and adjacent uninvolved bladder tissue from 7 patients, including 4 who underwent treatment with anti-PD-L1. Analyzing CD8+ T cells, the researchers found that the phenotypic states and TCR repertoires remained largely the same between tumors and adjacent nonmalignant tissue. In contrast, analysis of CD4+ T cells showed evidence of cytotoxic and regulatory tumor-specific states as well as heterogeneity within known CD4+ T cell states. The results were recently published in Cell.

To investigate the contribution of CD4+ T cells to antitumor responses, Oh and Kwek et al. sequenced and analyzed 16,995 tumor-infiltrating CD4+ T cells and 2,847 CD4+ T cells from adjacent tissue. Using this whole-transcriptome data, the researchers identified 11 clusters, each of which represented cells from all patients. These clusters defined several known CD4+ T cell states, including CCR7-expressing central memory cells and exhausted cells expressing high CXCL13 and IFNG, whose presence has been associated with improved outcomes in other cancers. Tregs (expressing Foxp3 and high levels of immune checkpoint molecules) were also identified within CD4+ T cells and were found to be abundant in tumors. The Treg population was not homogeneous; regulatory CD4+ T cells were distinguishable by either high or low expression of IL2RA and were found to consist of distinct proliferating (Ki67+) and non-proliferating states.

In addition to regulatory T cells, Oh and Kwek et al. identified cytotoxic CD4+ T cells in two distinct states: one marked by high expression of GZMB, and one marked by high expression of GZMK. In both states, these cytotoxic CD4+ T cells expressed IFNG. Some GZMB-expressing cells co-expressed TNF, CXCR6, PRF1, and high levels of NKG7. They did not express TOX or regulatory molecules. Using flow cytometry, the researchers confirmed that the majority of CD4+CCR7- cells were polyfunctional and could produce both IFNγ and TNFα, resembling cytotoxic CD8+ T cells. In another analysis using bulk expression data from carefully sorted T cell populations, CD4+ TILs expressing GZMB were found to be most similar to tumor-specific CD8+ T cells expressing ENTPD1 (CD39), whereas CD4+ TILs expressing high GZMK were most similar to central memory or naive CD8+ T cells. Like Tregs, CD4+ T cells in both cytotoxic states were also found to be significantly enriched in tumors (although to a lesser extent than Tregs) and appeared to consist of distinct proliferating and non-proliferating states.

Further analyzing CD4+ T cells, Oh and Kwek et al. performed paired alpha and beta chain TCR sequencing on the same cells. Overall, the TCR repertoire was more restricted in tumors than in adjacent non-malignant tissue. When TCR sequences were assigned to clusters, the researchers observed evidence of notable clonal expansion within Tregs and CXCL13-expressing CD4+ T cells from tumors, but little sharing of expanded clonotypes between Tregs and cytotoxic cells. Tumor-specific clonal expansion of cells suggests that cytotoxic CD4+ T cells might expand in response to tumor antigens presented on MHC-II. Of note, most bladder tumor cells expressed MHC-II, which would allow antigen recognition by CD4+ T cells.

Investigating whether cytotoxic CD4+ T cells might contribute to antitumor immunity, Oh and Kwek et al. isolated CD4+ TILs from a patient and cultured them ex vivo with IL-2. When these expanded CD4+ T cells were cocultured with autologous tumor cells, they produced granzymes and perforin and induced tumor cell apoptosis. This effect was further enhanced when Tregs were removed from the culture of CD4+ T cells, suggesting that Tregs have a suppressive effect on autologous cytotoxic CD4+ T cells. When MHC-II was blocked in these cocultures, tumor cell apoptosis was reduced, suggesting that the response to tumor cells is dependent on the recognition of antigens presented on MHC-II.

To determine whether cytotoxic CD4+ T cells contribute to antitumor responses in patients with bladder cancer, Oh and Kwek et al. identified genes that were differentially expressed between different branches of CD4+ T cells observed in pseudotime, which grouped cells as proliferating cytotoxic CD4+ T cells, non-proliferating cytotoxic CD4+ T cells, or regulatory T cells. From this, the researchers developed a gene signature for cytotoxic CD4+ T cells and tested its predictive value to checkpoint therapy responses. Using bulk RNAseq data on tumor samples from 244 patients enrolled in a phase II clinical trial of atezolizumab for metastatic bladder cancer, the researchers found that the gene signature for cytotoxic CD4+ T cells correlated with response to anti-PD-L1 therapy in inflamed tumor samples, but not immune-excluded or immune desert samples.

The data collected by Oh and Kwek et al. suggest that tumor-infiltrating cytotoxic CD4+ T cells may expand in response to recognition of antigens presented on MHC-II and that they play an important role in bladder cancer and in the response to anti-PD-L1 immunotherapy. The work also shows that these cytotoxic CD4+ T cells are suppressed by intratumoral Tregs, which may limit antitumor responses. This information could be useful in evaluating patients likely to respond to immunotherapy, as well as designing future immunotherapy and combination therapies in bladder cancer, and possibly in other solid tumors with MHC-II expression and limited responses to immunotherapy.

by Lauren Hitchings


Oh D.Y., Kwek S.S., Raju S.S., Li T., McCarthy E., Chow E., Aran D., Ilano A., Pai C.S., Rancan C., Allaire K., Burra A., Sun Y., Spitzer M.H., Mangul S., Porten S., Meng M.V., Friedlander T.W., Ye C.J., Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 3.

In the Spotlight...

Targeting Lymph Node Niches Enhances Type 1 Immune Responses to Immunization

Using microscopy, flow cytometry, adoptive cell transfer, and gene-modified mice, Lian et al. showed that emulsification of antigen (Ag) + Th1-skewing TLR4 agonist in incomplete Freund’s adjuvant rapidly, but passively, deposited s.c. injected Ag in cortical interfollicular regions (IFRs) ringing B cell areas of draining lymph nodes. CCL2 induced in IFRs attracted inflammatory monocytes, which became Ag+ and, when signaled by type I IFN, made CXCL10 to attract CD4+ T cells from the paracortex/T cell zone to the IFR/B cell areas. There, CD4+ T cells interacted with CCR7-dependent IL-12+DCSIGN+MHCII+ DC migrants to induce robust IFNγ/TNFα Th1 responses.

Contributed by Paula Hochman

High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D

Sim et al. analyzed five KRAS-G12D-specific, tumor-infiltrating TCRs from two patients, who were treated with ex vivo-expanded TILs (one achieved tumor regression). All TCRs were HLA-C*08:02-restricted, and recognized a nonamer or a decamer peptide from the mutated KRAS. Only G12D, but not WT, KRAS peptides were presented on HLA-C*08:02. All five TCRs exhibited high (but varying) binding affinities to the peptide-HLA-C complex, and TCR affinity inversely correlated with in vivo persistence. Determination of TCR and pHLA-C structures provided a molecular basis for the shared antigen specificity among TCRs with different affinities.

Contributed by Anna Scherer

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-gamma, CXCL9 and CXCL10

Bergamaschi et al. explored the mechanisms by which heterodimeric IL-15/IL-15Rα (hetIL-15) improved MC38 and TC-1 tumor control. Without altering Tregs, hetIL-15 treatment increased CD8+ T cell and NK cell tumor infiltration, proliferation, and cytotoxic phenotype; both CD8+ and CD4+ T cells had higher GzmB and IFNγ expression. HetIL-15 therapy upregulated various chemokines within tumors, particularly XCL1 and CXCL9/10 in cytotoxic (NK and CD8+) and myeloid cells, respectively. HetIL-15 led to increased tumor infiltration of cDC1s, which also secreted CXCL9/10 in an IFNγ-dependent manner, suggesting a positive feedback loop with T and NK cells.

Contributed by Alex Najibi

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

Walker et al. used bilateral tumor models of colon carcinoma (CT26) and fibrosarcoma (MCA-205) to assess the efficacy of single flank, high-dose radiotherapy (RT) and systemic NKTR-214 (CD122-biased PEGylated IL-2) combination. NKTR-214/RT synergized to reduce irradiated as well as contra-lateral unirradiated tumor growth, and cured 58%-86% animals. The antitumor response of the combination therapy was dependent on CD8+ T cells, but not CD4+ T cells, and partially on NK cells. NKTR-214/RT increased cytotoxic CD8+ T cell expansion, proliferation (Ki-67+), and effector function (IFNγ, TNFα, and granzyme A) at both irradiated and abscopal sites.

Contributed by Shishir Pant

Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion

Hughes and Lauder et al. used the 4T1 mouse breast cancer model to examine the impact of relief from immune suppression by Treg depletion on lung metastatic disease in the presence or absence of the primary breast tumor. Treg depletion in 4T1 tumor-bearing mice resulted in primary tumor regression and decreased lung metastases (mets), dependent on control of the primary tumor. However, if the primary tumor was surgically removed prior to Treg depletion, there was no effect on lung mets. The studies suggest the primary tumor and lung mets respond differently to Treg depletion, and additional approaches may be required to control metastatic growth.

Contributed by Katherine Turner

TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models

Using two murine colon cancer models (CT26 and MC38), Case et al. evaluated the in vivo efficacy of anti-TNFR2 antibody as monotherapy and in combination with anti-PD-1. Anti-TNFR2 in combination with anti-PD-1 demonstrated the best tumor reduction, with 62% and 70% cure rate in CT26 and MC38, respectively. The enhanced efficacy of anti-TNFR2 in combination with anti-PD-1 was accompanied by decrease in Tregs and increase in CD8+ T cell/Treg ratio. Co-administration of anti-TNFR2 with anti-PD-1 was the best schedule, with 70% cure rate compared to anti-TNRF2 followed by anti-PD1 (40%), and anti-PD-1 followed by anti-TNRF2 (10%).

Contributed by Shishir Pant

Everything New this Week In...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.